English

OYSTER POINT PHARMA, INC.

EDGAR

OYST Quarterly report (10-Q) · filed 2022-11-10

16 filing records in this dataset, filed from 2019-10-04 to 2022-11-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

5.59 million USD

2022 Q3 · USD

Exact inputs and evidence

Revenue: 5591000 USD Source

Operating margin

-606.56%

2022 Q3 · %

Exact inputs and evidence

Operating Income: -33913000 USD Source
Revenue: 5591000 USD Source

Operating cash flow

-36 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -124506000 USD Source
Operating Cash Flow: -88535000 USD Source

Free cash flow

-36 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -124506000 USD Source
Operating Cash Flow: -88535000 USD Source
Capital Expenditure: 203000 USD Source
Capital Expenditure: 203000 USD Source

Cash and cash equivalents: 68.8 million USD 2022-09-30 Source
Exact value

68800000 USD
Long-term debt including current maturities: 92.2 million USD 2022-09-30 Source
Exact value

92218000 USD
Shares outstanding: 26.8 million shares 2022-09-30 Source
Exact value

26831485 shares

Reported share-count change

2.83% · 737 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

26094253 shares · 2021-09-30· Source
26831485 shares · 2022-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

19.6 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Revenue: 24539000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 17943000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 2700000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 4693000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 5591000 USD · 2022-07-01 – 2022-09-30 Source

Net income

-177 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Net income: -100659000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -58595000 USD · 2021-01-01 – 2021-09-30 Source
Net income: -47892000 USD · 2022-01-01 – 2022-03-31 Source
Net income: -49942000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -36747000 USD · 2022-07-01 – 2022-09-30 Source

Capital expenditure

438 thousand USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Capital expenditure: 1485000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 1250000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 85000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 203000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 85000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 203000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 203000 USD · 2022-01-01 – 2022-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-11-10.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2021-12-31
Operating income: 4 of 11 periods available· newest 2021-12-31
Net income: 4 of 11 periods available· newest 2021-12-31
Operating cash flow: 4 of 11 periods available· newest 2021-12-31
Capital expenditure: 4 of 11 periods available· newest 2021-12-31
Total assets: 2 of 11 periods available· newest 2021-12-31
Total liabilities: 2 of 11 periods available· newest 2021-12-31
Current assets: 2 of 11 periods available· newest 2021-12-31
Current liabilities: 2 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2021-12-31
Shares outstanding: 2 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 24.54 million

Prior period

USD 0

2020-01-01 – 2020-12-31
Current period

USD 24.54 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

24539000 − 0 = 24539000 USD

0 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
24539000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Year-over-year change in Revenue: 24539000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 24539000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1056243 Filing: 000172072522000028 Input fundies:Revenue: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1057529 Filing: 000172072522000028
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 30.14 million

Prior period

−USD 70.52 million

2020-01-01 – 2020-12-31
Current period

−USD 100.66 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-100659000 − -70520000 = -30139000 USD

-70520000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-100659000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Year-over-year change in Net income: -30139000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -100659000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1635538 Filing: 000172072522000028 Input fundies:NetIncome: -70520000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1636710 Filing: 000172072522000028
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 30.97 million

Prior period

−USD 58.4 million

2020-01-01 – 2020-12-31
Current period

−USD 89.37 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-89370000 − -58399000 = -30971000 USD

-58399000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-89370000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Year-over-year change in Operating cash flow: -30971000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -89370000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1190766 Filing: 000172072522000028 Input fundies:OperatingCashFlow: -58399000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1191812 Filing: 000172072522000028
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+112.1%

Prior period

USD 700,000

2020-01-01 – 2020-12-31
Current period

USD 1.49 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

1485000 − 700000 = 785000 USD

700000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
1485000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Year-over-year change in Capital expenditure: 785000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1485000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1193570 Filing: 000172072522000028 Input fundies:CapitalExpenditure: 700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1194554 Filing: 000172072522000028
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 24.54 million 100% of revenue
Cost of revenue USD 1.53 million 6.2% of revenue
Operating expenses USD 119.67 million 488% of revenue
Operating income −USD 96.66 million −394% of revenue
Tax, interest and other Derived USD 4 million 16% of revenue
Net income −USD 100.66 million −410% of revenue

Cash

Operating cash flow −USD 89.37 million −364% of revenue
Capital expenditure USD 1.49 million 6.1% of revenue
Free cash flow Derived −USD 90.86 million −370% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 494% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	0	70989000 Derived	-70989000	-469000 Derived	-70520000	-59099000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -70989000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -70520000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -58399000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 700000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	24539000	121194000 Derived	-96655000	4004000 Derived	-100659000	-90855000 Derived	Source 2021-01-01 – 2021-12-31: 24539000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -96655000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -100659000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -89370000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1485000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 24.5M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	24539000	Revenue: 24539000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 24539000 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -393.9% 2021

Net margin -410.2% 2021

Free cash flow margin -370.2% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -70989000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-393.9%	Operating Income: -96655000 Open source Revenue: 24539000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -70520000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-410.2%	Net Income: -100659000 Open source Revenue: 24539000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -58399000 Open source Capital Expenditure: 700000 Open source
20212021-12-31	Free cash flow margin	-370.2%	Revenue: 24539000 Open source Operating Cash Flow: -89370000 Open source Capital Expenditure: 1485000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -89.4M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-58399000	Operating Cash Flow: -58399000 Open source
20212021-12-31	Operating cash flow	-89370000	Operating Cash Flow: -89370000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -90.9M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-59099000	Operating Cash Flow: -58399000 Open source Capital Expenditure: 700000 Open source
20212021-12-31	Free cash flow	-90855000	Operating Cash Flow: -89370000 Open source Capital Expenditure: 1485000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

55.3% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	5.7%	Total Liabilities: 11251000 Open source Total Assets: 197910000 Open source
20212021-12-31	Liabilities / assets	55.3%	Total Liabilities: 123080000 Open source Total Assets: 222617000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.47× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	17.88×	Current Assets: 196367000 Open source Current Liabilities: 10982000 Open source
20212021-12-31	Current assets / current liabilities	7.47×	Current Assets: 215250000 Open source Current Liabilities: 28802000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 16.5 million Exact value Exact value: -16503000 USD 2018-01-01 – 2018-12-31: -16503000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OYSTER POINT PHARMA, INC. · 2018-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Net Income: -16503000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16503000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072520000006/oyst-20191231.htm#2166450 Filing: 000172072520000006 The citation records this snapshot. The page link may show a newer release later.	−USD 17.08 million Exact value Exact value: -17083000 USD 2018-01-01 – 2018-12-31: -17083000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OYSTER POINT PHARMA, INC. · 2018-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Operating Cash Flow: -17083000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17083000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072520000006/oyst-20191231.htm#1671273 Filing: 000172072520000006 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2018-01-01 – 2018-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OYSTER POINT PHARMA, INC. · 2018-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072520000006/oyst-20191231.htm#1675727 Filing: 000172072520000006 The citation records this snapshot. The page link may show a newer release later.	−USD 17.08 million Calculation and evidence -17083000 − 0 USD Exact free cash flow: -17083000 USD 2018-01-01 – 2018-12-31: -17083000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OYSTER POINT PHARMA, INC. · 2018-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Free cash flow: -17083000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17083000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072520000006/oyst-20191231.htm#1671273 Filing: 000172072520000006 Input fundies:CapitalExpenditure: 0 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072520000006/oyst-20191231.htm#1675727 Filing: 000172072520000006 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 45.71 million Exact value Exact value: -45711000 USD 2019-01-01 – 2019-12-31: -45711000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OYSTER POINT PHARMA, INC. · 2019-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Net Income: -45711000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45711000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072521000023/oyst-20201231.htm#1470798 Filing: 000172072521000023 The citation records this snapshot. The page link may show a newer release later.	−USD 40.82 million Exact value Exact value: -40815000 USD 2019-01-01 – 2019-12-31: -40815000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OYSTER POINT PHARMA, INC. · 2019-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Operating Cash Flow: -40815000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40815000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072521000023/oyst-20201231.htm#1156882 Filing: 000172072521000023 The citation records this snapshot. The page link may show a newer release later.	USD 200,000 Exact value Exact value: 200000 USD 2019-01-01 – 2019-12-31: 200000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OYSTER POINT PHARMA, INC. · 2019-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Capital Expenditure: 200000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 200000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072521000023/oyst-20201231.htm#1159576 Filing: 000172072521000023 The citation records this snapshot. The page link may show a newer release later.	−USD 41.02 million Calculation and evidence -40815000 − 200000 USD Exact free cash flow: -41015000 USD 2019-01-01 – 2019-12-31: -40815000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 200000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OYSTER POINT PHARMA, INC. · 2019-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Free cash flow: -41015000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40815000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072521000023/oyst-20201231.htm#1156882 Filing: 000172072521000023 Input fundies:CapitalExpenditure: 200000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072521000023/oyst-20201231.htm#1159576 Filing: 000172072521000023 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 70.52 million Exact value Exact value: -70520000 USD 2020-01-01 – 2020-12-31: -70520000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OYSTER POINT PHARMA, INC. · 2020-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Net Income: -70520000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70520000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1636710 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.	−USD 58.4 million Exact value Exact value: -58399000 USD 2020-01-01 – 2020-12-31: -58399000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OYSTER POINT PHARMA, INC. · 2020-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Operating Cash Flow: -58399000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -58399000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1191812 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.	USD 700,000 Exact value Exact value: 700000 USD 2020-01-01 – 2020-12-31: 700000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OYSTER POINT PHARMA, INC. · 2020-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Capital Expenditure: 700000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1194554 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.	−USD 59.1 million Calculation and evidence -58399000 − 700000 USD Exact free cash flow: -59099000 USD 2020-01-01 – 2020-12-31: -58399000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 700000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OYSTER POINT PHARMA, INC. · 2020-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Free cash flow: -59099000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -58399000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1191812 Filing: 000172072522000028 Input fundies:CapitalExpenditure: 700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1194554 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 100.66 million Exact value Exact value: -100659000 USD 2021-01-01 – 2021-12-31: -100659000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Net Income: -100659000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -100659000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1635538 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.	−USD 89.37 million Exact value Exact value: -89370000 USD 2021-01-01 – 2021-12-31: -89370000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Operating Cash Flow: -89370000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -89370000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1190766 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.	USD 1.49 million Exact value Exact value: 1485000 USD 2021-01-01 – 2021-12-31: 1485000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Capital Expenditure: 1485000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1485000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1193570 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.	−USD 90.86 million Calculation and evidence -89370000 − 1485000 USD Exact free cash flow: -90855000 USD 2021-01-01 – 2021-12-31: -89370000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1485000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OYSTER POINT PHARMA, INC. · 2021-12-31 OYSTER POINT PHARMA, INC. (edgar:1720725) Free cash flow: -90855000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1720725?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -89370000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1190766 Filing: 000172072522000028 Input fundies:CapitalExpenditure: 1485000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1720725/000172072522000028/oyst-20211231.htm#1193570 Filing: 000172072522000028 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

16 filings · 975 latest values · 975 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001720725, 1720725, OYST, edgar:1720725

Also known as OYSTER POINT PHARMA, INC., Oyster Point Pharma, Inc.

OYSTER POINT PHARMA, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation